07:00 , Jun 21, 2010 |  BC Week In Review  |  Company News

Arginetix, Immune Control deal

Arginetix and Immune Control merged to form Corridor Pharmaceuticals Inc. The newco will develop therapies for vascular diseases, initially focusing on pulmonary arterial hypertension (PAH). Corridor, which will be based in Baltimore, has designated Immune...
07:00 , Jun 21, 2010 |  BioCentury  |  Finance

Friendly persuasion

Arginetix Inc. and Immune Control Inc. agreed to merge last week in a union officiated by Quaker BioVentures, which saw an opportunity to combine a pair of early-stage portfolio companies in the same space. Gary...
00:22 , Jun 18, 2010 |  BC Extra  |  Company News

Arginetix, Immune Control merge, raise $15 million

Arginetix Inc. (Baltimore, Md.) and Immune Control Inc. (West Conshohocken, Pa.) merged to form Corridor Pharmaceuticals Inc. and raised $15 million in a series A round. The combined company is developing therapies for vascular diseases,...